Brenda Jarrell on Recent Rulings Effect on Personilized Medicine

Genetic Engineering & Biotechnology News

 | May 1, 2009

 | Brenda Jarrell

View "Recent Decisions Curtail Personalized Medicine"


Brenda Jarrell, partner and chair of life sciences,  wrote “Recent Decisions Curtail Personalized Medicine,” published in Genetic Engineering & Biotechnology News.  The article offers a forward-looking analysis of how recent rulings might shape the nascent personalized medicine industry, making it a case study on how legal rules can impact business behavior and shape the development of an industry.

Personalized medicine represents a fundamental shift in the drug development modus operandi: a movement away from creating drugs that prove safe and effective in a majority of patients towards drugs tailor-made for individuals or small groups based on their genetic information.  But the Bilski ruling implies that such therapies would not be patent-eligible, while the Levine ruling has increased the liability exposure for all pharmaceutical companies.  Dr. Jarrell does not argue that the personalized medicine industry is doomed, just that it must adapt to significant legal challenges.   


Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.